| Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1. 1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. S Grissmer, AN Nguyen, J Aiyar, DC Hanson, RJ Mather, GA Gutman, ... Molecular pharmacology 45 (6), 1227-1234, 1994 | 1002 | 1994 |
| Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid H Rollema, LK Chambers, JW Coe, J Glowa, RS Hurst, LA Lebel, Y Lu, ... Neuropharmacology 52 (3), 985-994, 2007 | 643 | 2007 |
| Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence H Rollema, A Shrikhande, KM Ward, FD Tingley Iii, JW Coe, BT O'Neill, ... British journal of pharmacology 160 (2), 334-345, 2010 | 181 | 2010 |
| Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1. 3 and suppress T cell activation. A Nguyen, JC Kath, DC Hanson, MS Biggers, PC Canniff, CB Donovan, ... Molecular pharmacology 50 (6), 1672-1679, 1996 | 156 | 1996 |
| UK‐78,282, a novel piperidine compound that potently blocks the Kv1. 3 voltage‐gated potassium channel and inhibits human T cell activation DC Hanson, A Nguyen, RJ Mather, H Rauer, K Koch, LE Burgess, ... British journal of pharmacology 126 (8), 1707-1716, 1999 | 110 | 1999 |
| Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo S Sivakumaran, RA Cardarelli, J Maguire, MR Kelley, L Silayeva, ... Journal of Neuroscience 35 (21), 8291-8296, 2015 | 105 | 2015 |
| Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the … CJ O’Donnell, BN Rogers, BS Bronk, DK Bryce, JW Coe, KK Cook, ... Journal of medicinal chemistry 53 (3), 1222-1237, 2010 | 97 | 2010 |
| High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors J McNeish, M Roach, J Hambor, RJ Mather, L Weibley, J Lazzaro, ... Journal of biological chemistry 285 (22), 17209-17217, 2010 | 83 | 2010 |
| The CHRNA5–A3–B4 gene cluster and smoking: from discovery to therapeutics G Lassi, AE Taylor, NJ Timpson, PJ Kenny, RJ Mather, T Eisen, ... Trends in neurosciences 39 (12), 851-861, 2016 | 78 | 2016 |
| Muscarinic suppression of the M-current is mediated by a rise in internal Ca2+ concentration A Kirkwood, MA Simmons, RJ Mather, J Lisman Neuron 6 (6), 1009-1014, 1991 | 60 | 1991 |
| The small molecule CLP257 does not modify activity of the K+–Cl− co-transporter KCC2 but does potentiate GABAA receptor activity RA Cardarelli, K Jones, LI Pisella, HJ Wobst, LJ McWilliams, PM Sharpe, ... Nature Medicine 23 (12), 1394-1396, 2017 | 50 | 2017 |
| Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206 DC Hanson, PC Canniff, MJ Primiano, CB Donovan, JP Gardner, ... Proc Am Assoc Cancer Res 45 (Abs), 3802, 2004 | 45 | 2004 |
| Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome JY Kang, J Chadchankar, TN Vien, MI Mighdoll, TM Hyde, RJ Mather, ... Journal of Biological Chemistry 292 (16), 6621-6632, 2017 | 44 | 2017 |
| Failure of neuroprotection despite microglial suppression by delayed-start myeloperoxidase inhibition in a model of advanced multiple system atrophy: clinical implications C Kaindlstorfer, P Sommer, B Georgievska, RJ Mather, AR Kugler, ... Neurotoxicity research 28, 185-194, 2015 | 42 | 2015 |
| Selectivity of the effects of guanosine-5'-O-(2-thiodiphosphate) on agonist inhibition of the M-current in amphibian sympathetic neurons MA Simmons, RJ Mather Journal of Neuroscience 11 (7), 2130-2134, 1991 | 31 | 1991 |
| Desensitization of the inhibition of the M-current in sympathetic neurons: effects of ATP analogs, polyanions, and multiple agonist applications MA Simmons, JB Becker, RJ Mather Neuron 4 (4), 557-562, 1990 | 29 | 1990 |
| The discovery of a novel phosphodiesterase (PDE) 4B-preferring radioligand for positron emission tomography (PET) imaging L Zhang, L Chen, EM Beck, TA Chappie, RV Coelho, SD Doran, KH Fan, ... Journal of Medicinal Chemistry 60 (20), 8538-8551, 2017 | 28 | 2017 |
| N-methyl-D-aspartate receptors, ketamine, and Rett syndrome: something special on the road to treatments? DM Katz, FS Menniti, RJ Mather Biological psychiatry 79 (9), 710-712, 2016 | 27 | 2016 |
| Galanin function in the central nervous system. KM Walton, JE Chin, AJ Duplantier, RJ Mather Current Opinion in Drug Discovery & Development 9 (5), 560-570, 2006 | 26 | 2006 |
| Tingley 3rd, FD, Williams, KE, 2007. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid H Rollema, LK Chambers, JW Coe, J Glowa, RS Hurst, LA Lebel, Y Lu, ... Neuropharmacology 52 (3), 985-994, 0 | 25 | |
